| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia 30322
Received 26 October 2006/ Accepted 14 December 2006
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Virulence factors of GAS that have been characterized include surface-exposed adhesins, proteins that aid in evasion of the host immune response, toxins (including those that lyse host cells and therefore produce further changes in the microenvironment), and enzymes (proteases and DNases) that enable the GAS to spread through host tissues (10). Expression of these virulence factors in response to environmental stimuli is controlled by several transcriptional regulators, including "stand-alone" regulators such as Mga and RofA/Nra, as well as two-component signal transduction systems (26). In the GAS genomes whose sequences are available, 13 different two-component regulatory systems have been identified. Several of these are global regulators that affect transcription of a large number of different promoters, both directly and indirectly.
However, for all pathways of transcriptional control of gene expression examined in the GAS, growth-phase regulation is epistatic to the specific regulatory mechanism being studied (4, 31). For all genes studied in this organism, any specific transcript is only present at a restricted phase of growth, even under the most favorable regulatory conditions (presence of an activator and absence of a repressor). Thus, it seems important to understand the mechanism for what has been called "growth-phase regulation."
As bacteria grow, they produce changes in their immediate environment that may trigger modifications in gene expression and entry into stationary phase. For example, when GAS are cultivated in the laboratory in Todd-Hewitt yeast extract broth, the pH drops as acid is produced from sugars, metabolic by-products accumulate in the medium, and specific nutrients are depleted, and it is also possible that specific "quorum-sensing" signals may be secreted (29, 30). Any of these environmental conditions may trigger the molecular alterations in the bacteria that occur on entry into stationary phase. Loughman and Caparon (28) found a correlation between genes expressed on entry into stationary phase in the laboratory with those expressed following subcutaneous infection in a murine model, which implies that events that occur during growth-phase transition are similar to those that occur during development of soft tissue infection. This suggests that an understanding of the mechanisms that control growth-phase regulation would be very helpful in understanding GAS pathogenesis.
It has long been recognized that most GAS mRNAs are not easily detectable in stationary phase when the cells are grown under standard laboratory conditions (21). A change in the transcriptome in stationary phase in most bacteria results from production of an accessory sigma factor (19). Its association with RNA polymerase leads to efficient transcription of some promoters and decreased transcription of others. However, because GAS lacks such a stationary-phase sigma factor, there must be a different explanation for phase-specific mRNA abundance in this organism. The amount of mRNA in a cell is determined by a combination of its rate of synthesis and its rate of decay. Although many studies have focused on the former, there are no reports yet on regulation of mRNA decay in the GAS. In this work, we found that, for the subset of transcripts studied, growth-phase-specific stability is the major contributor to growth-phase regulation.
| MATERIALS AND METHODS |
|---|
|
|
|---|
RNA manipulations. RNase protection assays (RPAs) were performed as described previously (11). The sequences of primers used for probe amplification are shown in Table S1 in the supplemental material. For mRNA decay experiments, rifampin was added to give 1 mg/ml and RNA was isolated and purified through a CsCl gradient as described previously (31). Primer extension was performed as described in reference 32, using primers sagA-PE2 (sagA) and sda-PE (sda). Primers are listed in Table S1 in the supplemental material. For Northern analysis, 5 µg total RNA was fractionated in 5% polyacrylamide-8 M urea gels and electroblotted to nylon membranes (Roche). An antisense 32P-labeled RNA probe was generated by in vitro transcription using T7 RNA polymerase (MaxiScript kit; Ambion) and a DNA template generated by PCR using MGAS315 DNA and primers sagA+1-S and T7sagA-R. Membranes were hybridized overnight in Ultrahyb buffer (Ambion) at 68°C and then washed twice in 2x SSC (1x SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-0.1% sodium dodecyl sulfate (SDS) and twice in 0.1x SSC-0.1% SDS at 68°C.
Construction of RNase mutant strains. The strategy for creation of nonpolar deletions/substitutions in pnpA, rnr and yhaM is described in the supplemental material (see Fig. S1 and primer sequences listed in Table S1 in the supplemental material). The final result is an internal deletion of the RNase gene and replacement of the deleted portion with a promoterless aad9 gene (from pUCSpec) (23) followed by a ribosome binding site and ATG in frame with the 3' coding sequence.
Construction of pnpA-complementing plasmid pJRS1290.
Plasmid pREG696 is a theta replicon-type plasmid carrying aad9 into which the postsegregation killing system encoded by axe-txe has been cloned (16). This is a single-copy plasmid, and, in GAS, less than 1 in 200 colonies lose the plasmid following overnight culture (C. Bates and J. Scott, unpublished data). The vector pJRS9508 was derived from pREG696 by cloning the P23 promoter from plasmid pOri23 (35) in front of a tyrA reporter gene (D. Zahner and J. Scott, unpublished data). To create a tetracycline-resistant derivative of pJRS9508, the aad9 gene was first deleted by inverse PCR using primers pREGaad9-F2-Bgl and pREGaad9-R2-Bgl. The 7-kb inverse PCR product was digested with BglII and ligated to a 3-kb BamHI
tetM fragment (34) from pJRS303 to create pJRS1289.
Plasmid pJRS1290 contains a copy of pnpA from MGAS315 cloned into pJRS1289 under the P23 promoter. pnpA (coding for polynucleotide phosphorylase [PNPase]) was amplified by PCR from MGAS315 DNA using primers pnpA-F4-Bam and pnpA-R4-Xho. The resulting PCR product was digested with BamHI and XhoI and ligated to BamHI-XhoI-digested pJRS1289, to create pJRS1290.
Construction of JRS1288. Construction of JRS1288, a derivative of MGAS315 that contains gene replacement mutations in sagA and covR, is described in the supplemental material.
Construction of Psag and Phas fusion plasmids pJRS1286, pJRS1287, and pJRS1293. The Phas-sag (pJRS1286), Psag-sag (pJRS1287), and Psag-hasABC (pJRS1293) fusions were constructed by PCR using MGAS315 genomic DNA as a template and the high-fidelity enzyme PlatinumTaq-HF (Invitrogen). For pJRS1286, the Phas-sag fusion was constructed by a two-step overlapping PCR protocol as described previously (2). First round DNA fragments were amplified using primers PhasM3-NotI-F and PhasM3-sag-R (Phas) and PhasM3-sag-F and sagA-DS-Bam-R (sagA). Primers PhasM3-sag-F and PhasM3-sag-R contain a complementary 27-nucleotide sequence which facilitated the fusion of first round products in a second round PCR using primers PhasM3-NotI-F and sagA-DS-XhoI-R2. For pJRS1287, Psag-sagA region was amplified directly from MGAS315 DNA using primers Psag-NotI-F2 and sagA-DS-XhoI-R2. The resulting DNA fragments from each of these PCRs were digested with NotI and XhoI and cloned into NotI+XhoI-digested pJRS9508, to create pJRS1286 (Phas-sag) and pJRS1287 (Psag-sag).
Similarly, for pJRS1293, the Psag-hasABC fusion was constructed by overlapping PCR using primers Psag-NotI-F2 and Psag-has-R (Psag) and Psag-has-F and hasC-DS-XhoI-R (hasABC) for first round reactions and Psag-NotI-F2 and hasC-DS-XhoI-R for a second round reaction. Primers Psag-has-F and Psag-has-R contain a complementary 30-nucleotide sequence, which allowed the fusion of first round PCR products in the second round reaction. The resulting DNA fragment was digested with NotI and XhoI and cloned into NotI-XhoI-digested pJRS1289, to create pJRS1293.
| RESULTS |
|---|
|
|
|---|
To compare two transcriptomes, some normalization process is required to adjust for variation between different experiments. Because the amount of most transcripts was very small or undetectable in stationary phase in our study, there were no transcripts expressed equally well in both growth phases that would have been suitable for normalization. Therefore, we performed a "phase-specific" global normalization: i.e., the amount in stationary phase was normalized to the total in stationary phase and similarly for exponential phase (see supplemental material). From this analysis, the ratios of relative mRNA abundance in stationary phase versus exponential phase for individual genes were comparable to those measured by RNase protection and other assays (13; data not shown), confirming the validity of the approach. The cutoff we employed to identify significant quantitative differences in transcripts between the two growth phases was sufficiently stringent to result in 0.028% false positives (see Fig. S3 in the supplemental material). However, this stringency may have resulted in lack of identification of some transcripts that are only slightly more abundant in stationary phase.
Using the above approach, we identified six genes whose transcripts constituted a greater fraction of the total mRNA 2 h into stationary phase than in late exponential phase (hereafter referred to as stationary-phase transcripts [SPTs]; Table 1), while the transcripts for 735 genes were less abundant in stationary phase than in exponential phase. The SPTs included two that had been previously identified, sagA and sda (13), thus validating the microarray results. In addition to these previously studied genes, we identified another member of the sag operon (sagI), genes encoded in a putative arginine deiminase operon (arcA and arcT), and a putative transposase (SPyM3_0221). These results were confirmed in independent experiments for three SPTs (sagA, sda, and arcT; Fig. 1 and Table 2) and three control transcripts (hasA, gyrA, and slo). The lack of identification of all members of the sag or arc operons may result either from processing of the transcript to fragments with different stabilities or from technical difficulties. We did not pursue this further.
|
|
|
As a control to demonstrate that rifampin is active in stationary phase, we needed a transcript that was detectable but unstable at that stage of growth. Because we thought the hasA transcript would be unstable in stationary phase, we sought a strong promoter from which it could be expressed at that growth phase. We chose Psag, since we observed a significant amount of sagA transcript in stationary phase. For this experiment, we constructed plasmid pJRS1293 in which Psag was placed in front of hasABC (Fig. 2A; see Materials and Methods). To further improve expression from this promoter, a covR mutant strain (JRS1288) was used because CovR represses Psag (13). We found that in JRS1288/pJRS1293, hasA mRNA was detectable in stationary phase and was unstable. Following the addition of rifampin 2 h after entry into stationary phase, the hasA transcript decayed with about the same kinetics as in the exponential phase (Fig. 2B and C and Table 2) (data not shown) Note that the half-life was about 6.6 min in stationary phase and 2.7 min in exponential phase.) This demonstrates that rifampin is active in stationary-phase cells and that mRNA decay can be measured at that stage of growth. Therefore, this control validates the conclusion that the transcripts of the SPTs sagA, sda, and arcT are more stable in stationary phase than in exponential phase.
|
The sizes of the sagA transcript are the same in exponential and stationary phases. Although the 5' ends of the sagA transcript are the same in exponential and stationary phases, it was possible that stationary-phase mRNA was cleaved downstream and did not include the entire sagA open reading frame. To test this, we performed a high-resolution Northern blot using a probe for sagA that includes the entire open reading frame (ORF) as well as the 5' untranslated region (UTR) (144 bases upstream of the ORF) and the 3' UTR (189 bases), including the presumed RNA polymerase pause site stem-loop structure (Fig. 3A). The hybridization experiment (Fig. 3B) showed that the sagA transcript is the same length in exponential and stationary phases and that there is little accumulation of mRNA of an intermediate size in either phase.
|
We were unable to detect any major difference in the decay rate of sda mRNA in the yhaM or the rnr mutant strains (data not shown), and these were not analyzed further. However, in the pnpA mutant (JRS1392), both SPT transcripts investigated (sagA and sda) decayed more slowly than they did in the parental strain (Fig. 4 and Table 3). However, it should be noted that these transcripts are more stable in stationary phase (Fig. 1) than in a pnpA mutant in exponential phase. As controls, hasA, slo, and gyrA were used. Little difference was observed in stability of these transcripts between the pnpA mutant and the wild-type parental strain (Table 3).
|
|
The stable sagA transcript in the pnpA mutant strain JRS1392 is full length. The sagA transcript detected by RPA in the pnpA mutant strain could be either the full-length transcript or a stabilized decay intermediate resulting from endonuclease cleavage. To differentiate between these two possibilities, we analyzed total RNA isolated from MGAS315 and JRS1392 at various times following rifampin addition by Northern blot analysis using the probe described above (Fig. 3A). There was no observable accumulation of stable decay intermediates in either strain in late exponential phase, and the stable decay intermediates detected in stationary phase were present in the wild type as well as the mutant and represent a minor fraction of the sagA mRNA (see Fig. S5 in the supplemental material). We conclude from these results that the sagA transcript measured in the RPA experiments is full length and that the absence of PNPase does not result in accumulation of a stable decay intermediate.
Initiation of transcription also plays a role in determining the amount of sagA mRNA in stationary phase. To gain insight into the contribution of transcription initiation to the abundance of sagA mRNA in stationary phase, we used the sagA transcript as a reporter of promoter activity since we have shown it to be stable in stationary phase. We investigated one promoter producing a message that is undetectable in stationary phase (Phas) and one producing an SPT (Psag). The Phas promoter fragment used includes the 10 element and 6 nucleotides downstream and is fused in front of the untranslated sagA leader (Fig. 5A). The sag DNA includes the sagA ORF and the region downstream, including 110 bases downstream of the transcriptional pause site that is present between sagA and sagB (Fig. 5A). For these experiments, the reporter fusion constructs were cloned into pJRS1289, a stable single-copy vector (see Materials and Methods). This allowed direct comparison of promoter strength based on the quantity of reporter sagA mRNA present. To ensure that the only sagA transcript produced would be that of the reporter, the chromosomal copy of the sagA gene was deleted from MGAS315. In addition, because both Phas and Psag are repressed by CovR, the covR gene was deleted to produce the strain used (JRS1288).
|
| DISCUSSION |
|---|
|
|
|---|
We confirmed the previous reports that the transcripts for the secreted virulence factors sagA and sda are more abundant in stationary phase. This is reminiscent of virulence factor regulation in Staphylococcus aureus, where most secreted virulence factors are predominantly expressed in stationary phase, while other virulence factors are predominantly transcribed in exponential phase. While their mechanisms of control may be completely different, it seems possible that increased stationary-phase production of secreted enzymes, with the concomitant decrease in the expression of adhesins, could favor the spread of these organisms through host tissues. This would also allow them to escape the poor local growth conditions that caused their initial entry into stationary phase to begin with.
We also identified transcripts for the arginine catabolism operon (arc) as being SPTs, in agreement with a proteomics analysis that identified the proteins encoded by these genes as more abundant in stationary phase (7). Increased expression of these genes may reflect the need to use arginine as an energy source when other carbon sources (e.g., glucose) become limited. In addition, utilization of arginine by this pathway has been shown to protect oral streptococci (5) and Lactobacillus sakei (6) against the harsh stationary-phase environment, either through the production of ammonia to neutralize the low pH or by a pH-independent mechanism.
Although we identified two transcripts in both the sag operon and the arc operon as more abundant in stationary phase, the other genes in these operons were not identified by our microarrays. This suggests that the stability of different parts of a polycistronic transcript may differ (1, 18). While differential decay rates of fragments generated by endonucleolytic cleavage of the sag and arc mRNAs could account for our observations, it should also be remembered that the stringency of the cutoff for our microarrays might lead to underreporting of transcripts more abundant in stationary phase.
Transcription initiation plays a role in stationary-phase abundance of sagA mRNA. It appears from our results using fusions to sagA as a reporter transcript that the sag promoter, Psag, is recognized and active in stationary phase, while the has promoter, Phas, may not be active at that stage of growth (Fig. 5). In late exponential phase, the promoters appear to have similar strengths, since the amount of sagA transcribed from Psag is within about twofold of that transcribed from Phas. In addition, the strengths of these promoters appear to be similar when transcribed in vitro using GAS RNA polymerase (15, 17). However, using a sagA reporter transcript, we found more mRNA when it is transcribed from Psag 2 h following entry into stationary phase than when it is transcribed from Phas (Fig. 5). Since the same message is produced from the two different promoters, mRNA stability should not affect the relative abundance of these transcripts. In addition, we were able to detect incorporation of 32P into sagA mRNA expressed from Psag when added to the growth medium 2 h after the onset of stationary phase (data not shown). Therefore, we conclude that Psag is active in stationary phase, while Phas may not be recognized well by RNA polymerase in stationary phase.
Growth phase-specific transcription from a promoter may result from growth-phase-specific repression and/or activation. For example, Psag may be repressed in exponential phase by a transcriptional regulator that becomes inactive later in growth. Several negative transcriptional regulators in GAS, including CovR (13), LuxS (29), Rgg (8), and FasX (25), influence the expression of one or more of the SPT genes. However, none seems to be specific for SPTs. Alternatively, or in addition, Psag may be up-regulated in stationary phase. Evidence for positive regulation of Psag comes from the demonstration of induction of this promoter during lag phase, when expression of most genes is normally very low, by the addition of spent culture medium from late exponential phase (30). However, this investigation did not examine whether this effect was specific for Psag or other SPTs. Because no transcriptional regulator was identified in our microarrays as an SPT, if a growth-phase-specific activator exists, it is probably only expressed transiently so that its mRNA is unable to be detected 2 h into stationary phase. However, although the mechanism is not yet known, our results demonstrate that differential transcription does play a role in growth phase-specific mRNA abundance, at least for the sagA SPT.
mRNA decay is of primary importance for growth phase-specific mRNA abundance. The steady-state level of an individual mRNA is determined both by its rate of synthesis and by its rate of decay. The results of this study suggest that differential mRNA stability is the major determinant of stationary-phase message abundance. This is supported by the finding that all three SPTs tested have dramatically increased stability in stationary phase while other transcripts remain unstable. Furthermore, in stationary phase, the amount of the SPT transcript for sagA is much greater than that of the control transcript for hasABC, even when both are transcribed from the same promoter. This conclusion is based on the need to use a large amount of RNA (20 µg) to detect the hasABC transcript (which decays rapidly) compared to the amount (100 ng) needed to detect the sag transcript (an SPT). Therefore, the stability of the mRNA synthesized from Phas has a greater effect on the abundance of the transcript from this promoter than does the strength of the promoter.
The SPTs we studied are much more stable in stationary phase than most mRNAs that have been investigated in bacteria. The half-lives of about 80% of the mRNAs of E. coli and B. subtilis are less than 8 min, as determined by global mRNA stability analyses (3a). Even for "stable" mRNAs, half-lives only in the range of 15 to 45 min have been reported (20, 22, 24). In contrast, in GAS, half-lives of SPTs ranged up to about 225 min in stationary phase.
Decay of SPTs. While there are differences in the mRNA decay pathways of E. coli and B. subtilis, message decay in both organisms is primarily initiated by endonucleolytic cleavage by an enzyme that recognizes the 5' end of a transcript, and this is usually the rate-limiting step in decay (9). The endonuclease cleavage products are then processively digested by 3'-to-5' exonucleases. This decay pathway was demonstrated by the accumulation of endonuclease cleavage products in exonuclease mutants (12, 33, 37).
To define the decay pathway for SPTs, we constructed mutations in each of three putative 3'-to-5' exonuclease genes. While deletion of the gene for either of the exonucleases encoded by rnr (RNase R) or yhaM had no major effect on SPT decay, deletion of the gene encoding polynucleotide phosphorylase had a dramatic effect on decay of sagA and sda, the two SPTs tested. In late exponential phase, these transcripts are more stable in a pnpA deletion mutant than in the parental wild-type strain (8.3-fold for sagA and 3.7-fold for sda), and their stability returns to the wild-type level when pnpA is provided in trans on a plasmid. The rate of decay of control transcripts that are not SPTs is not significantly affected by the pnpA deletion. Since PNPase appears to be required for SPT decay, but some other RNase is able to substitute for PNPase for the decay of other transcripts, it appears that SPTs are not subject to digestion by the pathway used for most GAS transcripts. We also note that there must be at least one additional RNase involved in decay of SPTs in exponential phase since SPTs are more stable in stationary phase than in a PNPase mutant.
Although mRNA decay is usually initiated by a 5' endonuclease cleavage, this does not seem to be the case for the SPT sagA. If this occurred, mutations in the exonuclease required for further decay should have resulted in accumulation of endonuclease cleavage products. However, for sagA, in the pnpA mutant in exponential phase, no decay products were detectable and the transcript remained full length. Furthermore, the 5' end of the sagA transcript in exponential phase, in which sagA mRNA decays, is identical to that in stationary phase and that produced in vitro from this promoter. Together, these results imply that at least this SPT is degraded by a different pathway from other GAS mRNAs and that PNPase is rate limiting for its decay. We expect, therefore, that in stationary phase, SPTs become stable because they are either protected from this specific decay pathway (27, 38) or because this pathway becomes defective or inactive in stationary phase.
Why are SPTs insensitive to the major GAS mRNA decay pathway? One reason SPTs are insensitive to the major GAS mRNA decay pathway may be that there is no internal site in SPTs that is susceptible to cleavage by the 5' endonuclease responsible for initiating decay of most GAS mRNAs. Alternatively, or in addition, the 5' end of SPTs may be inaccessible to the endonuclease because of RNA secondary structure or because the message is associated with a protein, a small RNA, or ribosomes. Rapid translation may also protect SPTs from decay. Further investigation is required to identify which of these factors is/are involved in insensitivity of SPTs to the major endoribonuclease of the GAS decay pathway.
Concluding remarks. Bacteria adapt to different niches by modifying gene expression in response to environmental stimuli. In GAS, growth-phase control of gene expression is superimposed on all other levels of gene regulation and therefore must be understood to begin to comprehend the interactions of this pathogen with its host. In this study, we demonstrated that in GAS, the rate of mRNA decay is the major factor affecting growth-phase mRNA abundance for the SPTs we studied. Although SPTs are degraded in exponential phase with kinetics similar to most GAS mRNAs, the pathway for SPT decay appears to be different. As the cells enter stationary phase, this pathway becomes defective, resulting in dramatically increased mRNA stability, while the bulk of GAS mRNAs are degraded normally. Further experimentation is required to identify the features of SPTs that make them insensitive to the normal decay pathway, to elucidate the molecular details of the pathway by which they decay, and to learn why this pathway is growth-phase specific.
| ACKNOWLEDGMENTS |
|---|
This work was supported in part by grant RO1-AI20723 from the National Institutes of Health.
| FOOTNOTES |
|---|
Published ahead of print on 22 December 2006. ![]()
Supplemental material for this article may be found at http://jb.asm.org/. ![]()
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Appl. Environ. Microbiol. | Infect. Immun. | Eukaryot. Cell |
|---|---|---|
| Mol. Cell. Biol. | J. Virol. | Microbiol. Mol. Biol. Rev. |
| ALL ASM JOURNALS |